Please try another search
Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPCPhase 2 dose expansion currently underway at the RP2CDs of masofaniten...
In a recent move that signals confidence in Matador Resources Co (NYSE:MTDR), the company's President of Land, A&D, Planning, Van H. Singleton II, has purchased shares worth approximately...
Matador Resources Co (NYSE:MTDR) Chairman and CEO Joseph Wm. Foran has made a significant purchase of the company's stock, according to a recent filing with the Securities and Exchange Commission....
Mettler-Toledo (MTD) came out with quarterly earnings of $5.77 per share, beating the Zacks Consensus Estimate of $5.71 per share. This compares to earnings of $5.12 per share a year ago. These...
Mettler-Toledo (MTD) came out with quarterly earnings of $5.16 per share, beating the Zacks Consensus Estimate of $5.09 per share. This compares to earnings of $4.65 per share a year ago. These...
Mettler-Toledo (MTD) came out with quarterly earnings of $5.12 per share, beating the Zacks Consensus Estimate of $4.99 per share. This compares to earnings of $4.36 per share a year ago. These...
Instrument Type
Region
Sector
Industry
Date
Category
Provider